Buy & Sell BIO-TECHNE Corp (TECH) – BIO-TECHNE Corp Price Today
Key Stats
- $8.45BMarket Cap
- HealthSector
- -28.51%3M Drawdown
- $8.54BEnterprise Value
- 0.59%Dividend Yield
- 65 daysTypical Hold Time
BIO-TECHNE Corp (TECH) is currently valued at a market capitalization of $8.45B, with an enterprise value of $8.54B. Over the past 52 weeks, BIO-TECHNE Corp has traded between a low of $43.31 and a high of $71.38, highlighting its annual price range. Over the past three months, BIO-TECHNE Corp has recorded a drawdown of -28.51%, reflecting recent price volatility. BIO-TECHNE Corp offers a dividend yield of 0.59%, with the most recent dividend of $0.08 paid on 18 May 26. On average, investors hold BIO-TECHNE Corp for approximately 65 days, indicating typical investor behavior on the platform.
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Most Recent News
Trading of Defiance Daily 2X Space ETF (SPCL) halted due to SpaceX IPO volatility.
Defiance ETFs announced a temporary trading halt of its Defiance Daily 2X Space ETF (SPCL) on the Cboe BZX Exchange starting June 14, 2026, due to significant market volatility linked to SpaceX's recent IPO and NASDAQ debut. The halt is expected to l...
Software prices jump 14.5% YoY as AI data centers drive chip demand and inflation rises.
In May, consumer prices for computer software and accessories surged 14.5% year-over-year, marking the largest increase since 2000. This spike is driven by AI data centers consuming most of the global chip supply, causing RAM prices to soar nearly 29...
Celldex's CDX-622 shows positive Phase 1 results, depleting mast cells and inhibiting inflammation pathways safely.
Celldex Therapeutics announced positive Phase 1 trial results for CDX-622, a novel bispecific antibody targeting soluble stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP). The drug showed rapid, dose-dependent reductions in serum tryptas...
